Mursla Bio Receives FDA Breakthrough Device Designation for EvoLiver Test
- Reflects the potential of EvoLiver test to improve early liver cancer detection among high-risk patients
- EvoLiver leverages Mursla Bio’s platform based on organ-specific extracellular vesicles circulating in blood
- Breakthrough status provides expedited review and closer collaboration with the FDA, ultimately enabling broader market reach and commercial adoption